The aim of this study was to investigate the current published work relating to the clinical benefits of the use of systemic azithromycin as an adjunct to non-surgical periodontal therapy. A published work search of PubMed, EMBASE and Cochrane Register of Controlled Trials up to 27 April 2016 was undertaken. The large degree of heterogeneity in the types of studies, treatment protocols, test subjects, sample size and exclusion criteria indicated that the use of narrative synthesis of all relevant studies was a valid method of review. Of the 194 eligible studies, 15 were found to be of relevance. The majority of studies demonstrated an additional clinical benefit when azithromycin is used as an adjunct to non-surgical periodontal therapy, particularly in deeper pockets (≥6 mm). In conclusion, the current body of research on the adjunctive use of systemic azithromycin in non-surgical periodontal therapy suggests there is a clinical benefit and that this benefit is greatest in deeper initial pockets (≥6 mm). The findings also suggest that future studies need to be more careful in subject selection to identify susceptible patients or at risk sites, both the immunoregulatory effects and antibiotic resistance of azithromycin needs to be reported, and that study populations need to be more homogeneous.
INTRODUCTION
The prevalence of moderate to advanced periodontal disease has been estimated to be between 12% and 27% of the population aged 35-44 years worldwide. 1 It seems likely that there is a very high economic cost for treatment of disease. 2 In addition, there is growing evidence that there is a cost to patients' systemic health, in particular cardiac and diabetic health, because of periodontal infections. 3 Periodontal disease can be treated using non-surgical therapy in many cases. 4, 5 However, it has been shown that access to deeper pockets to provide adequate root surface debridement is more difficult and therefore results of non-surgical therapy in pockets of 7 mm or more are less predictable. 6, 7 It has also been suggested that in pockets of 7 mm or more there is a greater need to undertake periodontal surgery to achieve longer term stability. 8 A need for periodontal surgical procedures to control disease has a high economic 2 and emotional cost. 9 It has been recognized that there is also a variation in an individual's susceptibility to periodontal disease. [10] [11] [12] [13] These studies suggest that approximately 8-20% of the population account for the majority of tooth loss as a result of periodontal disease. Various hypotheses have been suggested to explain this variation in susceptibility and these include the presence of a more pathogenic microbial flora, 14, 15 an altered immune response to microbial plaque 16, 17 and genetic susceptibility. 18 Considerable interest has been generated recently by the identification of processes that control the active resolution of inflammation 19 and it has been suggested that individuals with a higher susceptibility to periodontal disease have a reduced ability to actively resolve inflammation in the periodontal tissues. [20] [21] [22] Clinical studies have been able to retrospectively identify individuals who respond poorly to conventional periodontal therapies. [23] [24] [25] [26] The current inability to prospectively identify these individuals 27, 28 means that much of the data evaluating the success and outcomes of conventional periodontal therapies includes individuals with high susceptibility and poor treatment response. Therefore, these studies may underestimate the clinical response of non-susceptible individuals and ascribe an unachievable response to individuals with high susceptibility. In addition to individuals who are naturally susceptible to chronic periodontal disease, a number of factors have been identified which can increase the susceptibility of an individual. These include smoking 29 and diabetes. 30, 31 Therefore, it is highly attractive to consider therapies that may enhance therapeutic outcomes in patients who have increased susceptibility to disease or conditions that are known to increase disease susceptibility.
It has been proposed that the use of systemic antibiotics may enhance the results of non-surgical therapy. 32 The use of antibiotics without conventional therapy has been shown to have no clinical benefit and that this is probably because the subgingival microbiome forms as a biofilm that is highly resistant to antibiotic therapy. 33 Tetracycline, minocycline, metronidazole, and metronidazole and amoxicillin combinations have been reported. 32 There have been studies demonstrating positive results with each of these adjuncts and there have also been a number of studies suggesting no additional benefit. Long dose time and minor but significant sideeffects of these antibiotics have been recorded. These factors have led to poor compliance. The nature of these antibiotics have also led to concerns about the development of antibiotic resistance. 32 Recently, it has been suggested that azithromycin (AZM) may be a useful adjunct to non-surgical periodontal therapy (NSPT). Its lower plasma concentration, few gastrointestinal tract complications, effectiveness against putative periodontal pathogens, simplified dose regime and proposed interaction with host response mechanisms involved in the control of the host response to periodontal pathogens have been suggested as reasons to contemplate the use of this drug in the treatment of periodontal diseases. 34 Case reports have suggested impressive clinical results in the treatment of advanced chronic periodontitis using AZM as an adjunct to NSPT. 35 The aim of this paper was to review whether current research supports the adjunctive use of AZM in NSPT to improve the outcome in deeper (≥6 mm) pockets, thus reducing the need for surgical therapy or supportive periodontal therapy.
MATERIAL AND METHODS

Search strategy
This systematic review was undertaken using the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 36 A careful online search was undertaken using the PubMed, Cochrane Register of Controlled Trials and EMBASE with no beginning date restriction and concluding at 27 April 2016. The search terms were 'azithromycin and periodontitis', 'azithromycin and periodontal disease', 'azithromycin and periodontal treatment' and 'azithromycin and periodontal therapy'. English-language articles only were accepted. No attempt was made to research unpublished articles. This search strategy was undertaken to identify studies that were relevant to support the aims of this paper.
Study selection
The search for studies revealed a moderate number of relevant studies (N = 194) of which 22 were considered to have relevance to the research question posed. Careful analysis of the abstracts and full text of these articles showed a great deal of heterogeneity in the types of studies, treatment protocols, test subjects, sample size and exclusion criteria. One paper was found to have no clinical data, one paper was identified that investigated the use of AZM as an adjunct to surgical therapy and a further five studies were found to investigate the use of AZM as a locally delivered antibiotic, and these studies were excluded on the basis of the altered mechanism of action or not helping to answer the question posed. It was decided that all of the remaining studies should be included, even if there were no subjects with probing depths greater than 6 mm, or the results for subjects with pockets of greater than 6 mm were not separately reported as there is a growing body of thought that a narrative synthesis of all relevant studies is a valid and useful method of review. 37, 38 The selection process is outlined in Fig. 1 .
Data collection
Relevant data from each of the studies was collected on standardized data forms. The data included authors' names, publication year, study design/type, geographical location of the study, participants' characteristics (age, gender, health status, smoking status), intervention undertaken, sample size, adverse events, inclusion and reporting of results in pockets of greater than 6 mm, and length of the study.
RESULTS
Characteristics of the included studies
A summary of the included studies is given in Table 1 . The included studies were published between 2002 and 2016, and included all studies that reported on clinical outcomes of the use of systemic AZM during this time period and reported clinical outcomes. A total of 15 studies were identified as having potential to provide evidence regarding the clinical benefit of the use of AZM in NSPT in pockets that are initially greater than 6 mm. The number of included subjects ranged from three to 80. One study was a case report. 35 Four studies were case-control reports. [39] [40] [41] [42] The remainder of the studies were randomized controlled trials with variable use of blinding and placebo using systemic AZM. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] The majority of the studies investigated the use of AZM in systemically healthy patients with slight to severe chronic periodontitis. 35, [40] [41] [42] [43] [44] 46, 47, 49, 51, 52 Ten studies included subjects with initial probing depths of greater than 6 mm. 35, 40, [43] [44] [45] [47] [48] [49] 52 One of these studies did not include separate reporting of the clinical outcomes in deeper initial pockets. 52 One study was identified using AZM for the treatment of periodontal disease in diabetic subjects. 50 
Clinical and microbiological effects
In subjects with chronic periodontitis, four of the 11 studies reported no improvement in clinical parameters over NSPT alone. 47, [49] [50] [51] All of these studies had a mixture of smokers and non-smokers in the subjects treated. Two of these studies were carried out in Turkey, one in Columbia, one in the USA and one in Brazil. All of these studies reported mean results of bleeding on probing (BOP), probing depth changes (ΔPD) and clinical attachment changes (ΔCAL). Of these studies, nine definitely included pockets of greater than 6 mm and one reported subjects with CAL of greater than 6 mm but probing depths of less than 6 mm. Smith et al. demonstrated a statistically significant improvement in PD (3.67 vs 4.54 mm) and BOP (45.2 vs 60.3%), with 6.9% of pockets not improving in the AZM group and 58.7% in the control group in pockets initially more than 6 mm. Similar clinical outcomes in deeper pockets were found in the other studies with statistically significant improvements in PD and BOP. 40, 44 However, Sampaio et al. reported no clinical or statistical improvement in pockets of more than 7 mm. 47 In aggressive periodontitis, two studies reported clinical improvements over NSPT alone 39, 45 and one reported no improvement. 48 Haas et al. reported on the results in deeper pocket (>7 mm) separately; while ΔPD, ΔCAL and BOP reductions were evident in the deeper pockets, these were not statistically significant. Emingil et al. reported on the percentage of pockets of more than 7 mm that improved by 3 mm or more with a statistically significant difference at 1 month 48 All of these studies had a mixture of smokers and non-smokers in the subjects treated and reported mean results of BOP, ΔPD and ΔCAL. The studies showing no improvement where undertaken in Brazil and Turkey.
Only one study was undertaken in smokers alone with chronic periodontitis and they found significant improvements in PD and BOP in pockets of greater than 6 mm. 40 One study was undertaken in diabetic subjects with poor metabolic control and the use of AZM did not improve clinical outcomes or glycaemic control. 50 Microbiological effects of the addition of AZM to non-surgical therapy was investigated in three studies with all showing significant reductions of putative periodontal pathogens in chronic periodontitis. 40, 46, 52 Of the studies that recorded the incidence of adverse effects, five studies reported an adverse event. 42, [44] [45] [46] 50 These included one case of a headache, three cases of diarrhoea in the AZM group and one case of diarrhoea in the placebo group.
DISCUSSION
The majority of studies found an additional benefit of using AZM as an adjunct to NSPT. In addition to this, when results were reported in pockets of greater than 6 mm, improvements in BOP and PD were reported in all studies; however, these were only statistically significant in four of the studies. This finding is confirmed by a recent meta-analysis which only included the RCT studies. 53 Forrest plots of ΔPD, ΔCAL and reduction of BOP demonstrated a definite advantage of AZM as an adjunct to non-surgical therapy using systemically delivered AZM. However, this data and method of analysis does not identify individuals who responded well to the addition of AZM. Indeed, the clinical significance of such findings are difficult to interpret because the large numbers of shallower pockets with little additional response to AZM can mask dramatic changes in deeper pockets of individuals. The authors of this meta-analysis acknowledge the heterogeneity of the RCT reviewed.
The majority of the studies undertaken to date have only investigated overall mean changes in clinical parameters. As NSPT has been shown to be extremely effective in PD of less than 5 mm, 4, 5 and these pocket depths are all of the pockets in slight to moderate chronic periodontitis and may be the majority of pockets even in advanced periodontitis cases, there is a very real concern that the additional clinical effect of AZM to non-surgical therapy in deeper pockets (>6 mm) might have been masked by the expected clinical effectiveness of NSPT in the shallower pockets. In studies which have reported separately on the results in deeper pockets (>6 mm), all have shown a marked reduction of putative periodontal pathogens 40, 46, 52 and significant improvement in PD, BOP and AL in deeper pockets (>6 mm). 40, 43, 44, 47, 49 Indeed, a recent meta-analysis by Zhang et al., 53 comparison of improvements in the clinical parameters of BOP, PD and AL in pockets of shallow, medium and deep pockets suggested that the majority of the clinical differences when using AZM as an adjunct to NSPT are as a result of the responses in deeper pockets.
This review has also found that despite excellent evidence of the potential positive effects of AZM in controlling some of the pro-inflammatory processes involved in periodontal disease, 34, 54 no clinical studies have been undertaken which report on changes in the local or systemic pro-resolving immunoregulatory profiles of patients treated with AZM in conjunction with NSPT. It is recognized that a small but significant proportion of the population that suffer from periodontal disease is susceptible to progressive disease. 11, 12 It appears that a significant proportion (30-80%) of this variation appears to be as a result of genetic variability 55 and that this is reflected as an inappropriate proinflammatory host response to microbial plaque. 21 These patients have been identified as having a higher risk of requiring surgical therapy and greater supportive periodontal therapy requirements, and even then are at risk of losing more teeth and having greater morbidity as a result of their periodontal disease. 28, 56 The ability to prospectively determine patient susceptibility to periodontal disease has been widely studied. Initial promise in identifying these susceptible patients using the 'red complex' bacteria (Porphyromonas gingivalis, Treponema denticola and Tannerella forsythia) was reported. 57 Subsequent studies have shown these 'red complex bacteria to be found in healthy and nonsusceptible patients', 58 and recent studies using sRNA to investigate subgingival plaque biofilms have shown enormous complexity and suggest that each patient has a unique microbiome and it is the patients response to this microbiome that determines susceptibility. 59 Genetic tests to identify susceptible patients have been developed 60 but these have proved to be unreliable in mixed populations. 18 However, much research is being undertaken in this field that hold promise for the future. 61 In addition to this, gingival crevicular fluid and saliva are being tested for pro-inflammatory markers to identify susceptible individuals but these methods have yet to be proven clinically relevant. 62 Thus, at the current time we are left to identify susceptible patients retrospectively and/or by their responses to therapy. 23 These patients may be the candidates in whom the use of AZM may be most helpful.
Some concern has been raised about the use of AZM because of its reported potential to cause cardiovascular death. 63 Further studies have confirmed that all macrolide antibiotics have the potential to cause cardiovascular complications but have shown that the incidence of these problems is extremely low and even then are only likely to occur in patients with already compromised cardiac conditions. [64] [65] [66] It would seem prudent not to prescribe AZM in patients with cardiac comorbidities and in particular patients with Q-T prolongation. The studies reviewed here only reported five complications with the use of AZM in 267 patients investigated and were slight gastrointestinal upsets and a headache.
Concerns have also been raised about the use of antibiotics because of the increasing incidence of antibiotic resistance. 67 It is interesting to note that the studies that have reported minimal or no effect of AZM originated in the USA and Brazil where there are high rates of AZM prescription for general medical infections 68 or in Spain and Turkey where AZM is available without prescription and high levels of AZM resistance have been documented. 69 It has been reported that when AZM is used as a single course for the treatment of periodontal disease there was an increase in antibiotic resistant bacteria initially but this returned to baseline at 12 months. 70 These findings suggest that careful use of antibiotics (including AZM) should be undertaken when prescribing for periodontal disease, and single courses should be used in patients who have been identified to be likely to benefit from treatment. Adjunctive antibiotics must not be seen as a routine requirement for NSPT.
CONCLUSIONS
The overall findings of this review show a positive effect of the use of AZM as an adjunct to NSPT. However, the heterogeneity of the study subjects makes identification of subjects and sites that may benefit most from the adjunctive use of AZM in NSPT impossible. Therefore, it appears to be important to undertake further clinical research in this field. These studies should identify prospectively or retrospectively subjects who have increased disease susceptibility and report on the results of adjunctive AZM use in NSPT in sites that would be considered for surgical therapy (i.e. PD >6 mm). They should also report on the in vivo immunoregulatory changes that may result with the use of AZM. Additionally, further studies should include the selection of patients who have not responded with resolution of BOP and reduction in PD as expected to NSPT. Development of such studies will also allow the investigation of the role of AZM in personalized therapies for periodontal treatment based on the clinical outcome of NSPT and the possibility of undertaking periodontal therapies with a treatment to target approach using clinical outcomes, microbiological outcomes or immune markers as the basis for the target to be achieved. 21, 71, 72 
